You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2024

Claims for Patent: 4,673,563

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 4,673,563

Title:	Adenosine in the treatment of supraventricular tachycardia
Abstract:	A method of diagnosing and treating arrhythmias caused by re-entry in the A-V node by administering to a human or animal an effective amount of adenosine that restores normal sinus rhythm.
Inventor(s):	Berne; Robert M. (Charlottesville, VA), Belardinelli; Luiz (Charlottesville, VA), Rubio; Rafael (Charlottesville, VA)
Assignee:	The University of Virginia Alumni Patents Foundation (Charlottesville, VA)
Application Number:	06/721,122
Patent Claims:	1. A method of treating supraventricular tachycardia caused by re-entry in the AV node, comprising the steps of: (a) administering intravenously to a human afflicted with the tachycardia, 0.01-0.25 mg/kg of body weight of adenosine sufficient to restore normal rhythm. 2. The method of claim 1, wherein said tachycardia is Wolff-Parkinson-White syndrome. 3. The method of claim 1, wherein said tachycardia is reciprocating junctional tachycardia. 4. The method of claim 1, wherein said amount is 1-8 mg. 5. The method of claim 1, wherein said amount is about 0.06 mg/kg. 6. A method of diagnosing supraventricular tachycardia caused by re-entry in the AV node, comprising the steps of: (a) administering intravenously to a human afflicated with the tachycardia 0.01-0.25 mg/kg of body weight of adenosine; (b) monitoring the heart beat of said human for restoration of normal sinus rhythm; and (c) determining the existence of the tachycardia. 7. The method of claim 6, wherein said tachycardia is Wolff-Parkinson-White syndrome. 8. The method of claim 6, wherein said tachycardia is reciprocating junctional tachycardia. 9. The method of claim 6, wherein said amount is 1-8 mg. 10. The method of claim 6, wherein said amount is about 0.06 mg/kg.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.